RxDoctor Payments Data

Sofia Garcia Buder, MD

Endocrinology, Diabetes & Metabolism · Chicago, ILNPI 1780622183

Payments from drug & device makers

$5,817in general payments, 2019–2025

Across 279 payments — averaging $20.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • Boehringer Ingelheim$1K
  • Sanofi-aventis U.S. LLC$616
  • Amgen$513
  • Merck$442
  • Johnson & Johnson$360
  • plus $2K from 14 others

What the payments were for

  • Food & beverage$5,70498%
  • Education$531%
  • Gifts$591%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,817 in reported general payments places this provider in the 75th percentile of 347 endocrinology, diabetes & metabolism providers in Illinois.

See all endocrinology, diabetes & metabolism providers in Illinois

Medicare billing

Part B allowed, 2024
$3,678
Medicare patients
11
Services billed
28

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin74$108,497
TradjentaLinagliptin40$50,633
Soliqua 100-33Insulin Glargine/Lixisenatide17$22,181
JanuviaSitagliptin Phosphate12$19,822
FarxigaDapagliflozin Propanediol11$11,260
NovologInsulin Aspart13$3,418
Metformin Hcl128$906
Glimepiride99$701
Repaglinide21$550
Metformin Hcl ErMetformin Hcl35$364
Levothyroxine Sodium49$335
Pioglitazone Hcl25$318
Methimazole32$228
Glipizide31$199

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$1,072$159,131114 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$616$22,18117 claims
MerckJanuvia$442$19,82212 claims
AstraZenecaFarxiga$114$11,26011 claims
Novo NordiskNovolog$1,124$3,41813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 347 endocrinology, diabetes & metabolism providers in Illinois.

Other endocrinology, diabetes & metabolism in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →